news

  • 12 September 2016
    Immunocore Ranked in the Sunday Times Hiscox Tech Track 100

    (Oxford, UK, 12 September 2016) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune disease, today notes that it has been ranked fourth overall in the 16th annual Sunday Times Hiscox Tech Track 100. Immunocore appears in the league table for the second time, rising up the rank from ninth place in 2015.

    The Sunday Times Hiscox Tech Track 100 league table ranks the top 100 private British technology, media and telecoms (TMT) companies with the fastest-growing revenues over the past three years. 

    The Tech Track 100 is compiled by Fast Track in association with The Sunday Times on an annual basis and adopts the London Stock Exchange’s techMARK definition of a technology company as one ‘that shows a commitment to innovation, research and product development, and operates in sectors including software, internet, telecoms and biotech’.

    Eva-Lotta Allan, Chief Business Officer at Immunocore, commented: “We are delighted that our continued growth and performance has been recognised through the inclusion in the prestigious Tech Track 100 for the second year running. This is an exciting time for Immunocore, and we are thankful for this continued support as we develop our portfolio of immuno-oncology and infectious disease assets and continue our mission to become a world leader in biotechnology.”